LIFA Ventures is a specialist Nordic venture capital firm and advisory, focused on early-stage medical devices and diagnostics.
We support founders developing technologies that improve patient outcomes and healthcare access, through both investment and hands-on collaboration.
The firm is in the process of establishing its first investment fund, LIFA Ventures Fund I, which is expected to focus on early-stage Nordic medical devices and diagnostics.
Our advisory arm, LIFA Partners, helps MedTech teams strengthen clinical, regulatory, and commercial readiness. We offer fractional access to help you strengthen regulatory, clinical, and commercial strategies before and after investment.
Our evaluation and support framework focuses on five key dimensions that determine early MedTech success.Great MedTech founders consistently get these five pillars right.
These five pillars define how we evaluate MedTech startups and guide our hands-on work with founders.
Smart MedTech founders start with clinical relevance, not just innovation. We look for founders who validate the unmet need early, engaging clinicians, patients, and payers to confirm both the pain point and the willingness to adopt. Market validation isn't about surveys; it's about evidence that your solution can improve outcomes and economics - not just locally, but globally.
Knowing how your product reaches patients is as important as the technology itself. We assess each company's strategy for pricing, distribution, and reimbursement - understanding who pays, who prescribes, and who benefits. The go-to-market pathway must reflect real-world workflows and health-economic logic. Early traction, pilots, and payer conversations turn clinical proof into commercial reality.
Product development in MedTech is never linear. We value founders who treat design, verification, and validation as a continuous learning loop - balancing speed with compliance. Early QMS building, clear development plans, milestone discipline, and data-driven iteration signal execution strength. Every iteration should move the device closer to market readiness, not just technical completion.
Winning in MedTech means designing with regulation in mind from day one. We invest in teams that understand their device classification, evidence requirements, and intended claims. A credible QMS, early FDA Q-Sub or NB dialogue, and well-defined clinical endpoints are key signals of a team ready for scale. Smart regulatory planning isn’t bureaucracy, it’s strategy based on your GTM pathway.
IP is more than patents, it’s your moat, your leverage, and your long-term value. We look for founders who align their IP strategy with their business model - covering not just the core technology, but key processes, data, and software layers. A strong freedom-to-operate analysis and active filing plan set apart teams who are building defensible MedTech companies, not just good ideas.
lifa@lifa.ventures
Reykjavik, Iceland
